Zoetis Inc. (NYSE:ZTS) Shares Acquired by Huntington National Bank

Huntington National Bank boosted its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 4.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 261,557 shares of the company's stock after acquiring an additional 12,310 shares during the quarter. Huntington National Bank owned 0.06% of Zoetis worth $42,616,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ZTS. Howard Capital Management Group LLC lifted its stake in Zoetis by 0.8% in the 3rd quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company's stock valued at $20,489,000 after buying an additional 883 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Zoetis by 17.3% during the third quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company's stock valued at $464,497,000 after acquiring an additional 351,372 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec lifted its position in shares of Zoetis by 5.1% in the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,051 shares of the company's stock valued at $401,000 after acquiring an additional 100 shares in the last quarter. Edgestream Partners L.P. acquired a new stake in shares of Zoetis in the third quarter worth approximately $2,078,000. Finally, Investment Management Corp of Ontario increased its position in shares of Zoetis by 176.9% during the third quarter. Investment Management Corp of Ontario now owns 40,589 shares of the company's stock worth $7,930,000 after purchasing an additional 25,931 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares of the company's stock, valued at approximately $2,682,770. The trade was a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock worth $312,254 in the last ninety days. 0.16% of the stock is owned by corporate insiders.

Zoetis Trading Down 4.9 %

Shares of NYSE ZTS traded down $7.85 during mid-day trading on Friday, reaching $151.76. 3,611,950 shares of the company's stock were exchanged, compared to its average volume of 2,599,526. The firm has a market capitalization of $67.96 billion, a price-to-earnings ratio of 27.74, a PEG ratio of 2.78 and a beta of 0.92. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.33. The company's 50-day moving average is $165.71 and its 200-day moving average is $173.58. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.32%. The ex-dividend date is Monday, April 21st. Zoetis's payout ratio is currently 36.56%.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Stifel Nicolaus lowered their price target on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a research report on Tuesday, January 7th. UBS Group assumed coverage on shares of Zoetis in a report on Monday, December 9th. They issued a "neutral" rating and a $196.00 price objective for the company. Morgan Stanley decreased their target price on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Finally, Piper Sandler upped their price target on Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Zoetis currently has a consensus rating of "Buy" and an average target price of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.